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KEYWORDS	
	 Benzodiazepines	 are	drugs	 used	 for	 treatment	 of	 several	 central	 nervous	 system	disorders,
such	as	anxiety	and	sleep.	In	spite	of	their	wide	and	popular	usage	in	clinics,	the	mechanism
explaining	why	a	certain	pharmacological	activity	 is	 superimposed	onto	another	 for	a	given
benzodiazepine	remains	unclear.	The	knowledge	of	the	conformation	of	benzodiazepines	and
their	 electronic	 charge	 distribution	 at	 molecular	 surfaces	 may	 give	 new	 insights	 into	 the
pharmaco‐benzodiazepine	 receptor	 interactions,	 contributing	 to	 the	 improvement	 of	 the
existing	 models.	 In	 the	 present	 study,	 the	 solid	 state	 geometric	 and	 conformational
parameters	of	the	available	X‐ray	benzodiazepine	structures	were	analyzed	and	reviewed.	The
electronic	features	of	two	groups	of	benzodiazepines	with	different	substituents	at	C7	and	C2’
positions	 were	 studied	 by	 DFT	 quantum	 chemical	 calculations.	 The	 conformations	 of	 the
molecules	 with	 optimized	 geometry	 were	 also	 analyzed.	 The	 relative	 charge	 distribution
around	 the	 benzodiazepinic	 rings	 and	 electrostatic	 potential	 mapped	 on	 electronic	 density
surfaces	 were	 obtained.	 The	 ring	 geometric	 parameters	 for	 the	 diazepine	 moiety	 in	 1,4‐
benzodiazepines,	do	not	vary	significantly	except	for	a	few	compounds	in	which	steric	and/or
intermolecular	 interactions	 play	 a	 part.	 The	 benzodiazepine	 ring	 assumes	 a	 pseudo‐
symmetrical	boat	conformation	and	the	torsion	angle	around	the	C5‐Ph	bond	varies	depending
on	the	nature	of	the	substituent	on	C2’.	Also,	the	presence	of	the	nitro	or	chloride	substituent
on	the	C7	position	and	the	presence	of	a	fluorine	atom	on	the	C2’	position	significantly	alter	the
relative	 charge	 distributions	 at	 the	 attached	 carbon	 atoms	 and	 the	 topology	 of	 the	 surface
electrostatic	potential.	
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1.	Introduction	
	
Benzodiazepines	 (BZs),	 a	 group	 of	 drugs	 widely	 used	 to	
treat	anxiety	and	sleep	disorders,	are	generally	represented	as	
in	 Figure	 1.	 Some	 of	 them	 also	 show	 remarkable	 activity	 as	
anticonvulsants	 and	myorelaxants.	 Anxiety	disorders	 (such	 as	
Generalized	Anxiety	Disorder	–	GAD,	Social	Phobia	–	SP,	Social	
Anxiety	 Disorder	 –	 SAD,	 Panic	 Disorder	 –	 PD,	 Obsessive–
Compulsive	Disorder	–	OCD,	Post–traumatic	 Stress	Disorder	–	
PTSD,	and	Specific	Phobias)	are	 the	most	common	psychiatric	
diseases	with	 incidence	 rates	of	 around	16%	to	25%	[1‐3].	 In	
fact,	 epidemiological	 studies	 have	 shown	 that	 anxiety	 is	 the	
second	leading	cause	of	depression	resulting	in	a	large	amount	
of	 work	 absenteeism	 and	 reduced	 productivity	 [2].	 Despite	
their	robust	anxiolytic	effect,	most	of	the	clinical	trials	with	BZs	
were	conducted	before	the	current	classification	for	the	anxiety	
disease	disorders	 came	 about.	As	 a	 result,	 knowledge	of	 their	
effectiveness	 in	 anxiety	 disorders	 may	 be	 incomplete	 and	
discrete.	In	clinical	practice,	BZs	are	used	in	generalized	anxiety	
disorder	with	diazepam	(1.a)	as	the	most	popular	choice	[1‐2].	
Response	 rates	 to	 therapy	 are	 high	 and	 the	 beginning	 of	 the	
therapeutic	 effect	 is	 immediate.	Alprazolan	 and	 clonazepam	
(2.b)	are	 the	only	BZs	approved	 for	 the	 treatment	of	SP	[4‐6],	
although	other	high‐potency	BZs,	such	as	lorazepam,	also	show	
similar	effects.	There	is	little	evidence	of	efficacy	of	BZs	in	OCD	
or	PTSD	and	no	BZ	was	approved	specifically	for	these	diseases	
[1].	
Anxiety	 disorders	 may	 affect	 the	 quality	 of	 sleep.	 Thus,	
drugs	 such	 as	 BZs	 are	 also	 widely	 used	 to	 treat	 insomnia	 as	
hypnotics.	In	fact,	they	represent	nowadays	the	most	important	
group	of	drugs	 involved	 in	 the	 treatment	of	 anxiety	and	sleep	
disorders	 [7].	BZs	 can	 also	 be	 used	 as	 anti‐convulsive	 and	
myorelaxants.	 All	 the	 BZs	 exhibit	 similar	 pharmacological	
profiles	but	differ	from	each	other	in	their	selectivity	and	thus,	
may	be	used	for	various	therapeutic	purposes:	this	arises	from	
the	 fact	 that	 they	 act	 as	 selective	 depressant	 on	 the	 central	
nervous	 system	 since	 they	 facilitate	 and	 increase	 the	
GABAergic	transmission	in	all	structures	of	the	Central	Nervous	
System	(CNS).	Also,	their	anxiolytic	or	hypnotic	properties	are	
difficult	to	differentiate	since	all	BZs	are	anxiolytic	and	may	act	
by	modifying	 sleep,	 provided	 they	 achieve	 certain	 doses.	 This	
overlap	 of	 the	 pharmacological	 activity	 makes	 it	 difficult	 to	
distinguish	 between	 true	 sedatives	 and	 anxiolytics,	 and	
classification	 of	 BZs	 as	 anxiolytic	 or	 sedative	 agents	 is	 deeply	
based	 on	 pharmacokinetic	 considerations	 related	 to	 the	 half‐
life	(t1/2)	of	these	drugs	[1].	
Anxiolytic	 substances	 and	 BZs	 currently	 on	 the	 market	
have	 been	 developed	 as	 a	 result	 of	 serendipity	 allied	 to	 a	
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rational	 molecular	 design.	 Molecular	 design,	 whose	 main	
objective	is	the	discovery	of	new	active	molecules,	 is	based	on	
provisional	 data	 concerning	 physical‐chemical	 characteri‐
zation,	 pharmacokinetics,	 pharmacodynamics,	 and	 studies	 of	
the	structure/activity,	even	before	synthesis	of	a	compound	in	
the	 laboratory.	To	 facilitate	 this	 molecular	 design	 process,	
knowledge	 of	 the	 structural	 features	 and	 physical	 chemical	
characteristics	 of	 actual	 active	 drugs	 are	 essential.	 Also,	 the	
knowledge	of	the	electronic	and	structural	features	of	BZs	may	
help	 on	 the	 understanding	 the	 affinity	 of	 BZs	 to	 specific	 sub‐
types	 of	 GABAA	 receptors	 [8‐12],	 thus	 helping	 on	 the	
systematization	of	their	main	therapeutic	activities.	
This	 work	 presents	 a	 review	 of	 the	 structural	
characteristics	 of	 BZs.	 The	 conformational	 analysis	 of	 the	
molecules	 is	 based	 on	 structures	 of	 1,4‐benzodiazepines	
obtained	 by	 single	 crystal	 X‐ray	 diffractometry	 that	 are	
available	 from	 the	 Cambridge	 Structural	 Database,	 CSD	 [13].	
Knowledge	 of	 the	 conformation	 of	 these	 drugs	 is	 important	
since	 former	 studies	 [14]	 show	 that	 BZs	 induce	 changes	 in	
conformation	in	the	α1	subunit	of	GABAA	receptors.	In	addition	
electronic	characterization	has	been	carried	out	for	two	sets	of	
BZs	 that	 were	 grouped	 on	 the	 basis	 of	 their	 C7	 position	
substitution	and	C2’	(refer	to	Figure	1),	using	quantum	chemical	
calculations.	 By	 doing	 this,	 inferences	 can	 be	 made	 about	
charge	density	distribution	in	the	molecule	and	the	mapping	of	
polar	moments	within	 the	molecule.	Although	 this	work	deals	
with	the	influence	of	substituents	on	the	C7	and	C2’	positions	on	
the	electronic	distributions,	the	compounds	chosen	are	limited	
to	 those	 with	 actual	 pharmacological	 action.	 The	 confor‐
mational	and	electronic	aspects	are	the	main	requirements	for	
BZs‐receptor	 interactions	 and	 knowledge	 of	 these	 can	
contribute	 to	 the	 improvement	 of	 the	 available	 proposed	
models	for	the	BZs‐GABAA	receptor	interaction.	
	
	
	 R1	 R2	 R7	 R2’
1.a	 –Me	 =O	 –Cl	 –H
1.b	 –N(Et)3	 =O	 –Cl	 –F
1.c	 –H	 =O	 –Cl	 –F
1.d	 –OH	 =O	 –Cl	 –F
2.a	 –H	 =O	 –NO2	 –H
2.b	 –H	 =O	 –NO2	 –Cl
2.c	 –Me	 =O	 –NO2	 –F
2.d	 –H	 =O	 –NO2	 –F
2.e	 –N(Et)3	 =O	 –NO2	 –F
2.f	 –Et	 –OH	 –NO2	 –F
	 	 	 	
Figure	1.	Molecular	scaffold	of	a	1.4‐dibenzazepine,	with	the	numbering	
of	atoms	and	identification	of	the	rings.	Compounds	studied	on	this	work	
are:	
	
2.	Experimental	
	
2.1.	Structural	analysis		
	
A	search	of	the	CSD	[13]	was	performed	using	the	5‐phenyl‐
1,4‐benzodiazepin‐2‐one	 moiety	 as	 a	 search	 fragment	
produced	68	organic	 structures	with	R‐factors	 of	10%	or	 less	
for	 which	 atomic	 co‐ordinates	 were	 supplied.	 Polymeric	 and	
powder	diffraction	structures	were	excluded	from	the	search	as	
were	duplicate	structures.	Tables	containing	the	CSD	reference	
codes	for	the	compounds	are	supplied	as	supplementary	data.	
	
2.2.	Computational	chemistry	
	
The	quantum	chemical	calculations	were	performed	for	10	
BZs	derivatives	(shown	in	Table	1)	with	the	program	Gaussian	
03	 [15].	 Geometrical	 optimizations	were	 carried	 at	 B3LYP/6–
311G++	(d,p)	level	of	 theory.	B3LYP	refers	 to	 the	combination	
of	functional	hybrid	exchange	of	Becke	[16]	with	the	functional	
correlation	 gradient	 of	 Lee	 &	 Yang	 [17].	 The	 notation	 6–
311G++	 (d,p)	 refers	 to	 a	 set	 of	split	 valence	 polarized	 bases	
[18].	 Since	 all	 the	 benzodiazepines	 with	 pharmacological	
interest	have	a	boat	conformation	for	the	diazepine	ring	in	the	
solid	 state	 and	all	 the	models	 concerning	 the	 interaction	with	
receptors	 are	 based	 on	 the	 boat	 conformation,	 this	 was	
assumed	as	the	starting	structure	for	optimization.	
For	the	same	level	of	theory,	vibrational	frequencies	for	all	
compounds	 were	 calculated	 to	 verify	 that	 the	 structure	
converged	to	a	minimum	using	the	zero	imaginary	frequencies	
criterion.	Molecular	orbitals,	as	well	as	the	charges	assigned	to	
each	 atom,	 were	 made	 by	 Natural	 Population	 Analysis	 Phase	
(NPA)	of	the	Natural	Bond	Orbital	analysis	(NBO)	according	to	
Carpenter	 [19].	 Molecular	 representation	 and	 ESP	 mapped	
surfaces	were	made	with	the	program	GaussView	3.0	[20].	
	
3.	Results	and	discussion		
	
3.1.	Structures	of	BZs	
	
The	 bond	 lengths	 in	 all	 85	 molecules	 for	 the	 68	 BZ	
structures,	in	some	structures	the	numbers	of	molecules	in	the	
asymmetric	 unit	 is	 greater	 than	 1,	 are	 in	 agreement	with	 the	
canonical	 structure	 in	 Figure	 1.	 Tables	 of	 bond	 lengths	 and	
angles	and	their	statistical	analysis	are	given	as	supplementary	
data.	 In	 all	 structures	 the	 diazepine	 ring	 adopts	 a	 boat	
conformation	with	a	pseudo‐reflection	plane	that	cuts	medially	
the	 C7–C8	 and	 C11–C10	 bonds	 of	 the	 diazepine	 and	 passes	
through	the	C3	atom	which	has	sp3	hybridization	(Figure	2).	
From	 the	 sixty	 eight	 structures	 analyzed,	9	 of	 them	had	 a				
–Br	 atom	 as	 substituent	 on	 the	 C7	 position,	 4	 of	 them	 were								
–NO2	substituted	and	8	substituted	with	–H.	The	remainder	had	
–Cl	as	a	substituent	on	the	C7	position.	In	the	case	of	atom	C2’,	
16	 of	 the	 BZs	 had	 –Cl	 as	 a	 substituent,	 2	 of	 them	 –F	 and	 the	
remainder	 an	 –H	 atom.	 Torsion	 angles	 T	 around	 the	 C5–Ph	
bond	 (Figure	3)	 show	a	 variation	within	 the	 [18‐47o]	 interval	
range	with	mean	value	of	32o	for	compounds	with	C2’–H	bond.	
Benzodiazepines	 with	 a	 chlorine	 atom	 on	 the	 C2’	 position	
exhibit	 a	 significant	higher	 torsion	angle	 lying	within	 the	 [51‐
76o]	 range	with	mean	 of	 63o.	 The	 only	 two	 structures	with	 a	
C2’–F	substituent	have	a	torsion	angle	of	43o.	
	
 
	
Figure	 2.	 Schematic	 representation	 of	 the	 “boat”	 conformation	 for	
benzodiazepines.	 The	 parameters	 adopted	 for	 the	 conformational	
analysis	 are	 a	 (the	 C10–C5–N4	 angle);	 b	 (the	 C5–N4–C3	 angle)	 and	 T	
(torsion	angle	around	bond	C5–Ph).	
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Table	1.	Common	name,	systematic	name	and	adopted	notation	for	benzodiazepines	belonging	to	Group	1	and	Group	2.	
Group	 Common	name	 Systematic	name	(International) Adopted	notation	
1	
Diazepam	1.a	 (RS)‐7‐chloro‐1,3‐dihydro‐
1‐methyl‐5‐phenyl‐	
1,4‐benzodiazepin‐2(2H)‐one.	
	
7‐Cl‐1‐Me‐2’H‐BZ	
	
Flurazepam	1.b	 (RS)‐7‐chloro‐1‐[2‐(diethylamino)ethyl]‐5‐(2‐
fluorophenyl)‐1,3‐dihydro‐2H‐1,4‐benzodiazepin‐2‐one	
	
7‐Cl‐1‐N(Et)3‐2’F‐BZ	
Desalkylflurazepam	1.c	 (RS)‐7‐chloro‐5‐(2‐fluorophenyl)‐1,3‐dihydro‐2H‐1,4‐
benzodiazepin‐2‐one	
	
7‐Cl‐2’F‐BZ	
Hydroxyethylflurazepam	1.d	 (RS)‐7‐chloro‐1‐[2‐(hydroxy)ethyl]‐5‐(2‐fluorophenyl)‐
1,3‐dihydro‐2H‐1,4‐benzodiazepin‐2‐one	
	
7‐Cl‐1‐OH‐2’F‐BZ	
2	
Nitrazepam	2.a	 (RS)‐9‐nitro‐ 6‐phenyl‐ 2,5‐diazabicyclo	[5.4.0]	undeca‐
5,8,10,12‐	tetraen‐	3‐one	
	
7‐NO2‐2’H‐BZ	
	
Clonazepam	2.b	 (RS)‐	5‐(2‐chlorphenyl)‐7‐nitro‐2,3‐dihydro‐1,4‐
benzodiazepin‐2(2H)‐one	
	
7‐NO2‐2’Cl‐BZ	
Flunitrazepam	2.c	 6‐(2‐fluorophenyl)‐ 2‐methyl‐ 9‐nitro‐ 2,5‐diazabicyclo	
[5.4.0]	undeca‐	5,8,10,12‐	tetraen‐	3‐one	
	
7‐NO2‐1Me‐2’F‐BZ	
Desmethylflunitrazepam	2.d	 6‐(2‐fluorophenyl)‐ 9‐nitro‐ 2,5‐diazabicyclo	[5.4.0]	
undeca‐	5,8,10,12‐	tetraen‐	3‐one	
	
7‐NO2‐2’F‐BZ	
Nitroflurazepam	2.e	 (RS)‐7‐nitro‐1‐[2‐(diethylamino)ethyl]‐5‐(2‐
fluorophenyl)‐1,3‐dihydro‐2H‐1,4‐benzodiazepin‐2‐one	
	
7‐NO2‐1‐N(Et)3‐2’F‐BZ	
Desalkylnitraflurazepam	2.f (RS)‐7‐nitro‐1‐[2‐ethyl]‐5‐(2‐fluorophenyl)‐1,3‐dihydro‐
3hydroxy‐2H‐1,4‐benzodiazepin‐2‐one	
7‐NO2‐1‐Et‐3OH‐2’F‐BZ	
	
	
	
	
1.a	
	
1.b	
	
	
	
1.c	
Figure	 3.	 Representation	 of	 the	 1.a,	 1.b and	 1.c obtained	 from	 gas	 phase	 geometry	 optimization	 carry	 out	 at				
B3LYP/6–311G++	(d,	p)	level	of	theory.	
	
When	 there	 is	 an	 H	 atom	 on	 N1	 these	 compounds	 form	
N1…O2	 dimers.	 In	 the	 presence	 of	 competitive	 donors	 or	
acceptors,	this	is	rarely	the	case.	In	other	cases,	when	there	are	
hydrogen	 donors	 or	 acceptors	 in	 substituents	 or	 in	 solvent	
molecules,	 the	 hydrogen	 bonding	 can	 become	 more	
complicated.	This	may	explain,	in	part,	the	divergence	of	bonds	
and	angles	from	the	norm	for	some	of	the	compounds.		
	
3.2.	Geometric	optimizations	
	
Geometry	 optimizations	 (in	 gaseous	 state)	 were	 made	
using	 the	 Gaussian	 03	 program	 [15],	 which	 performs	 the	
optimization	 of	 the	 geometry	 of	 the	 molecule	 by	 Density	
Functional	Theory	 (DFT)	methods.	The	 geometry	 is	 optimized	
as	 a	 criterion	 of	 the	 minimization	 of	 energy	 of	 the	 molecule,	
calculated	by	quantum	chemical	methods.	
In	order	to	evaluate	the	structural	and	electronic	effects	of	
–NO2	 and	 –Cl	 substituents	 at	 the	 C7	 position	 and	 the	 effect	 of					
–H,	 –Cl,	 and	 –F	 substituents	 at	 the	 C2'	 positions	 in	 BZs,	the	
compounds	were	 grouped	 into	 two	 sets	 as	 shown	 in	 Table	 1:				
i)	the	first	consists	of	the	compounds	with	a	C7–Cl	substitution,	
the	 reference	 compound	 used	 being	 diazepam,	 ii)	 the	 second	
consists	 of	 compounds	 with	 a	 C7–NO2	 substitution,	 the	
reference	compound	being	nitrazepam.	The	first	group	consists	
of	 diazepam	 1.a,	 flurazepam	1.b,	 and	 the	 desalkylflurazepam	
1.c,	 hydroxyethylflurazepam	 1.d,	 (last	 two	 being	 the	 active	
metabolites	 of	 flurazepam).	The	 second	 group	 consists	 of	
nitrazepam	 2.a,	 clonazepam	 2.b,	 flunitrazepam	 2.c	 and	 its	
active	 metabolite	 desmethylflunitrazepam	 2.d	 as	 well	 as	
nitroflurazepam	2.e	and	desalkylnitraflurazepam	2.f	(the	latter	
two	compounds	are	not	used	as	commercial	BZs).	
Since	 the	common	names	 for	benzodiazepines	do	not	give	
any	 information	 about	 the	 nature	 of	 substitutions	 on	 the	
benzodiazepine	ring,	the	discussion	of	the	results	will	be	made	
based	on	the	notation	shown	in	Table	1.	
The	 optimized	 structures	 belonging	 to	 both	 groups,	
obtained	 for	minimization	of	 the	 total	electronic	energies,	and	
their	 atom	 coordinates	 are	 supplied	 as	 supplementary	
information.	
The	 optimized	 geometry	 for	 7–Cl–1–Me–2’H–BZ	 (1.a),	 for	
7–Cl–1–N(Et)3–2’F–BZ	 (1.b),	 and	 for	 7–Cl–1–2’F–BZ	 (1.c)	 are	
given	 as	 examples	 in	 Figure	 3.	 The	 geometries	 do	 not	 differ	
significantly,	 except	 for	 the	 conformation	of	 the	 aromatic	 ring	
at	C5.	The	values	obtained	for	the	lengths	of	bonds	of	the	same	
nature	 do	 not	 differ	 significantly	 within	 the	 structures	
studied.	In	the	aromatic	ring,	the	BZ	Car	bond	lengths	are	typical	
of	 those	 found	 in	 aromatic	 rings.	 The	 imine	 and	 secondary	
amide	bond	distances	of	the	diazepine	ring	are	also	within	the	
normal	 range.	 Bond	 distances	 and	 angular	 values	 are	 also	
comparable	 to	 those	 obtained	 experimentally	 by	 X‐ray	
structural	 analysis,	 although	 being	 slightly	 and	 systematically	
increased.		This		feature		that		can		be		attributed		to	the	fact	that		
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Table	2.	Values	obtained	for	a,	b	and	T	angles	(refer	to	Figure	3),	obtained	at	B3LYP/6–311G++	(d,	p)	level	of	theory	as	well	as	their	dipole	moments	(Debye)	in	
gas	phase.	
Compound	 	 a	(°)	 b	(°)	 T	(°)	 D(D)
G1		
Diazepam	1.a	 7‐Cl‐1‐Me‐2’H‐BZ 123.4(7) 118.7(7) 31(1)	 2.30
Flurazepam	1.b	 7‐Cl‐1‐N(Et)3‐2’F‐BZ 124.3(7) 118.5(7) 49(1)	 4.14
Desalkylflurazepam	1.c	 7‐Cl‐2’F‐BZ	 136.8(7) 119.6(7) 50(1)	 4.21
Hydroxyethylflurazepam	1.d 7‐Cl‐1‐OH‐2’F‐BZ 124.1(7) 118.5(7) 46(1)	 3.74
G2	
Nitrozepam	2.a	 7‐NO2‐2’H‐BZ 124.5(7) 119.7(7) 33(1)	 1.35
Clonazepam	2.b	 7‐NO2‐2’Cl‐BZ 126.1(7) 119.7(7) 62(1)		 2.47
Flunitrazepam	2.c	 7‐NO2‐1Me‐2’F‐BZ 124.4(7) 118.5(7) 48(1)	 3.20
Desmethylflunitrazepam	2.d 7‐NO2‐2’F‐BZ 126.7(7) 119.6(7) 50(1)	 2.35
Nitroflurazepam	2.e	 7‐NO2‐1‐N(Et)3‐2’F‐BZ 124.2(7) 118.2(7) 47(1)	 3.95
Desalkylnitraflurazepam	2.f	 7‐NO2‐1‐Et‐3OH‐2’F‐BZ 125.7(7) 119.5(7) 50(1)	 2.74
	
Table	3.	Charge	distributions	(e‐)	calculated	by	NPO	at	B3LYP/6–311++G(d,p)	level	of	the	BZs	gas	phase.		
	 Compound	 C7	 C11 N1 C=O N4	 C5	 C2’
G1		
7‐Cl‐1‐Me‐2’H‐BZ	1.a	 ‐0.066 +0.179 ‐0.491 ‐0.601 ‐0.428	 +0.269	 ‐0.195
7‐Cl‐1‐N(Et)3‐2’F‐BZ	1.b	 ‐0.063 +0.180 ‐0.495 ‐0.607 ‐0.398	 +0.262	 +0.464
7‐Cl‐2’F‐BZ	1.c	 ‐0.069 +0.168 ‐0.654 ‐0.590 ‐0.405	 +0.266	 +0.444
7‐Cl‐1‐OH‐2’F‐BZ	1.d	 ‐0.062 +0.178 ‐0.496 ‐0.604 ‐0.399	 +0.263	 +0.446
G2	
7‐NO2‐2’H‐BZ	2.a	 +0.045 +0.199 ‐0.650 ‐0.578 ‐0.430	 +0.272	 ‐0.194
7‐NO2‐2’Cl‐BZ	2.b	 +0.046 +0.201 ‐0.649 ‐0.577 ‐0.402	 +0.275	 ‐0.026
7‐NO2‐1Me‐2’F‐BZ	2.c	 +0.048 +0.212 ‐0.486 +0.586 ‐0.398	 +0.266	 +0.447
7‐NO2‐2’F‐BZ	2.d	 +0.045 +0.200 ‐0.649 +0.576 ‐0.403	 +0.268	 +0.446
7‐NO2‐1‐N(Et)3‐2’F‐BZ	2.e	 +0.044 +0.213 ‐0.491 ‐0.590 ‐0.396	 +0.264	 +0.448
7‐NO2‐1‐Et‐3OH‐2’F‐BZ	2.f	 +0.043 +0.234 +0.481 ‐0.589 ‐0.444	 +0.292	 +0.446
	
optimization	 in	 gaseous	 phase	 does	 not	take	 the	 effects	 of	
intermolecular	 interactions	 due	 the	 crystal	 packing	 into	
account.	
	
3.2.1.	Conformation	of	the	DFT	optimized	structures	
	
The	 benzodiazepines	 in	 this	 study	 show	 the	 typical	
conformation	 for	 the	 diazepine	 ring.	 This	 conformation	 does	
not	 change	 significantly	 with	 the	 type	 of	 substituents.	As	
mentioned	above,	Section	3.1,	the	diazepine	ring	adopts	a	boat	
conformation	with	a	pseudo‐reflection	plane	that	cuts	medially	
the	 C7–C8	 and	 C11–C10	 bonds	 of	 the	 diazepine	 and	 passes	
through	 the	 C3	 atom	 having	 the	 sp3	 hybridization	 (Figure	 2).	
The	valence	angles	involving	the	N4	atom	are	close	to	120o,	the	
overall	geometry	of	its	neighborhood	is	flat	and	the	bond	length	
is	 typical	 of	 a	 double	 C=N	 bond.	On	 the	 opposite	 side	 of	 the	
molecule,	 the	 carbonyl	 carbon	 atom	 of	 the	 set	 N1–(C=O)	
similarly	has	a	 flat	 triangular	geometry.	The	conformation	can	
be	characterized	by	 three	angles,	 the	angle	a	 formed	between	
the	C11–C5–N4	atoms,	the	angle	b	between	the	C5–N4–C3	atoms,	
and	 the	 torsion	 angle	T	defined	 as	 the	 angle	 N4‐C5‐C1’‐C2’.	The	
general	conformation	adopted	is	represented	in	Figure	2	where	
7–NO2–2'H–BZ,	 2.a,	 was	 chosen	 as	 an	 example.	 Table	 2	
summarizes	 the	 geometrical	 parameters	 a,	 b,	 and	 T	 for	 each	
compound.	 The	 angle	 b	 does	 not	 vary	 with	 the	 type	 of	
compound	neither	does	angle	a	with	the	exception	of	7–Cl–2’F–
BZ,	1.c,	whose	angle	a	 of	136.6	 (8)°	 is	higher	 than	 that	of	 the	
remaining	 BZs.	 On	 the	 other	 hand,	 the	 angle	 between	 the	 C5	
phenyl	 ring	 plane	 and	 the	 aromatic	 benzodiazepine	 residue	
plane	 varies	 from	 compound	 to	 compound.	This	 variation	 is	
quantified	by	 the	 torsion	 angle	T,	 around	C5–Ph	bond	 (Figure	
3).	An	analysis	of	this	value	suggests	that	it	is	dependent	on	the	
nature	of	the	substituent	present	on	the	atom	C2'	of	the	phenyl	
ring.		
When	the	substituent	is	a	hydrogen	atom,	as	 is	the	case	of	
7–Cl–1–Me–2’H–BZ,	 1.a,	 and	 7–NO2–2’H–BZ,	 2.a,	 the	 torsion	
angle	is	about	30o.	When	the	substituent	is	a	fluorine	atom,	this	
angle	 increases	 to	 lie	 in	 the	 46–50°	range.	BZ	 7–NO2–2’Cl–BZ,	
2.b,	presents	the	highest	value	(60o)	of	twist	angle	around	the	
C5–Ph	 bond.	These	 variations,	 which	 probably	 reflect	 the	
electrostatic	repulsions	that	exist	between	the	electronic	clouds	
of	 halogens	 and	 the	 unoccupied	 orbital	 of	 the	 imine	 nitrogen	
atom,	are	also	observed	in	the	set	of	crystalline	structures	that	
were	 analyzed.	It	 is	worth	 noting	 that	 the	modification	 of	 the	
conformation	 of	 the	 molecule	 may	 affect	 the	 extent	 of	 its	
linking	 to	 a	 pharmacologically	 active	 site,	 therefore	 affecting	
the	pharmacological	activity	of	the	drug.		
	
3.3.	Polarity	and	charge	distributions	
	
The	 dipole	moments	 obtained	 for	 the	 studied	 compounds	
are	given	in	Table	2.	It	appears	that	the	compounds	containing	
a	 chlorine	 atom	 in	 position	 C7	 have	 a	 higher	 dipole	 moment	
than	 those	 with	 a	 nitro	 group	 in	 the	 same	 position.	Also,	 the	
existence	of	a	fluorine	atom	at	position	C2’	and	the	introduction	
of	 a	 polar	 substituent	 at	 the	 nitrogen	 atom	 N1	 increase	 the	
polarity	of	the	BZ.	
In	 addition	 to	 the	 dipole	moment,	 it	 is	 also	 of	 interest	 to	
analyze	the	relative	charge	distribution	among	the	atoms	of	the	
molecule.	These	relative	distributions	may	indicate	preferential	
binding	 sites	 on	 the	 hydrophilic	 or	 lipophilic	 regions	 of	 the	
receptor.	 Moreover,	 they	 can	 determine	 sites	 of	 the	 receptor	
regions	at	which	polarity	could	be	more	easily	induced.	
The	atomic	charges	were	calculated	by	Natural	Population	
Analysis	 (NPA)	 [19]	 using	 the	 same	 level	 of	 theory	 as	 for	
geometrical	 optimizations.	 The	 values	 obtained	 for	 selected	
atoms	 in	compounds	1.a‐e	and	2.a‐f	are	summarized	 in	Table	
3.	Since	 such	 charge	 distributions	were	 calculated	 for	 the	 gas	
phase	 geometries	 care	must	 be	 taken	 in	 the	 analysis	 of	 their	
absolute	 values.	However,	 the	 resultant	 simplifications	
introduced	 by	 the	 model	 do	 not	 preclude	 the	 validity	 of	 the	
discussion	based	on	relative	comparisons.	
	
3.3.1.	Charge	distribution	at	N1	
	
The	 most	 negative	 atomic	 areas	 on	 the	 molecule	 become	
more	 sensitive	 to	 acidic	 coordination.	The	 negative	 charge	
distributions	are	often	due	 to	 inductive	effects	of	 substituents	
such	 as	 alkyl	 chains	 or	 other	 sigma	 electronic	 density	
donors.	This	 seems	 to	 be	 the	 case	 for	 the	 nitrogen	 atom	 N1	
where	 the	presence	of	 an	alkyl	 substituent	 significantly	 alters	
the	 charge	 distribution	 in	 the	 atom,	 decreasing	 its	 polarity	
thereby	 making	 a	 molecule	 with	 lower	 donor	 ability	 in	 this	
region.	
	
3.3.2.	Charge	distribution	at	C7	
	
The	variation	of	 the	charge	distribution	at	carbon	atom	C7	
shows	 that	 the	 electron	 density	 withdrawing	 effect	 of	 nitro	
group	 is	 superior	 to	 chlorine.	Thus,	 the	 charges	 on	 C7	 for	
compounds	belonging		to		the		G1		group	are	slightly	negative	or		
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1.a	 	
1.b	
Figure	4.	 The	 electrostatic	 potential	 (ESP),	mapped	on	 an	 electron	density	 surface	 (that	was	
given	 by	 SCF)	 for	1.a	 (7‐Cl‐1‐Me‐2'H‐BZ)	and	 for	1.b	 (7‐Cl‐1‐N	 (Et)	 3‐2'F‐BZ).	The	 positively	
charged	regions	are	blue	and	green	while	regions	with	higher	electron	density	are	mapped	from	
red	to	yellow.	The	isovalue	taken	was	0.04	e/Å3.	
	
	
	
2.a	
	
	
2.b	
	
	
	
2.c	
Figure	5.	The	electrostatic	potential	(ESP),	mapped	on	an	electron	density	surface	(that	was	given by	SCF)	for	2.a	(7‐Cl‐1‐
Me‐2'H‐BZ),	for	2.b	7‐NO2‐2’Cl‐BZ	and	2.c,	7‐NO2‐2’F‐BZ.	The	positively	charged	regions	are	blue	and	green	while	regions	
with	higher	electron	density	are	mapped	from	red	to	yellow.	The	isovalue	taken	was	0.04	e/Å3.	
	
	
very	close	to	neutrality.	However,	C7	in	G2	group	compounds	is	
slightly	 electropositive	 due	 to	 the	 negative	 inductive	 effect	 of	
the	nitro	group,	since	the	sp2	hybridization	of	this	group	allows	
the	flow	of	the	electron	cloud	to	the	oxygen	atoms.	
	
3.3.3.	Charge	distribution	at	C2'		
	
The	 effect	 of	 variation	 in	 charge	 on	 the	 C2’	 carbon	 atom	
seems	 to	be	more	pronounced	 for	 the	C–F	bond	 as	 compared	
with	 C–H	 and	 C–Cl	 bonds.	 In	 fact,	 by	 comparing	 the	 atomic	
charges	at	carbon	atom	C2	'	in	the	presence	and	absence	of	the	
fluorine	 atom,	 it	 appears	 that	 the	 C–F	 bond	 reverses	 the	
polarity	 of	 the	 carbon	 atom	 C2'	 making	 it	 quite	 electro‐
positive.	The	replacement	of	a	hydrogen	atom	of	a	hydrocarbon	
by	a	fluorine	atom	significantly	influences	the	physicochemical	
properties	 of	 this	 compound.	The	 fluorine	 atom	 is	 more	
electronegative	than	the	hydrogen	atom	and	its	atomic	volume	
is	 also	 much	 higher:	 the	 van	 der	 Waals	 radius	 for	 hydrogen	
atom	 is	 1.20	 Å,	 while	 for	 fluoride	 is	 1.47	 Å.	 The	 high	
electronegativity	 of	 fluorine	 atom	 and	 the	 similarity	 of	 its	
orbital,	in	terms	of	size	and	energy	on	the	carbon	atom,	allows	
for	 a	 very	 strong	 bond.	Thus,	 the	 carbon–fluorine	 bond	 is	 the	
highest	energy	at	which	a	carbon	atom	can	participate	[21,22].	
The	 difference	 in	 electronegativity	 between	 the	 carbon	 and	
fluorine	 atom	 generates	 a	 large	 dipole	 moment	 which,	 if	
combined	 with	 the	 electrostatic	 distribution	 of	 a	 specific	
molecule,	 may	 contribute	 to	 the	 ability	 of	 the	 molecule	 to	
participate	 in	 intermolecular	 interactions.	 This	 is	 particularly	
true	in	aromatic	systems,	examples	of	which	are	the	BZs,	where	
the	introduction	of	a	fluorine	atom	modifies	the	distribution	of	
electrostatic	surface	of	 the	molecule	and	may	also	 induce	new	
potential	 binding	 sites	 on	 the	 molecule	 in	 question	 located	
close	of	fluorine	atoms.	
	
3.4.	Isoelectronic	potential	surfaces		
	
Concerning	 ligand‐receptor	 binding	 (drug‐receptor)	 not	
only	 the	 polarity	 of	 the	 molecule	 or	 its	 electronic	 charge	
distribution	should	be	envisaged.	The	approach	of	 the	drug	 to	
the	 receptor	 for	 linking	 is,	 possibly,	 carried	 out	 by	 a	 process	
that	 involves	 the	 presence	 of	 a	 cavity	 in	 the	 active	 site,	 the	
establishment	 of	 intermolecular	 connections	 (that	 can	 be	 of	
electrostatic	 nature	 or	 hydrophobic/hydrophilic	 interactions),	
and	 a	 possible	 rearrangement	 of	 the	 active	 site	 due	 to	 the	
above	mentioned	interactions.	Since	this	is	a	dynamic	process,	
the	 charge	 distribution	 on	 the	 molecular	 surface	 could	
probably	play	an	important	role	in	the	establishing	of	the	drug‐
receptor	interaction.	Molecules	can	exhibit	different	molecular	
electronic	 charge	 distributions	 depending	 on	 the	radial	
distance	 to	 the	 atoms	 nuclei.	Thus,	 a	 group	 that	 is	 "a	 strong	
attractor	 of	 electron	 density"	 can	 localize	 the	 negative	 charge	
over	 a	 distance	 closer	 to	 the	 core	 than	 a	 weaker	 attractor	 of	
that	 density.	Consequently,	 the	 effect	 of	 the	 less	 electron	
attractor	 group	 density	 on	 the	 approach	 to	 a	 receptor	 can	
prevail	over	the	former.		
The	 electrostatic	 potential	 surfaces	 obtained	 for	 the	
representative	compounds	are	depicted	in	Figure	4	and	5.	
The	 large	 red	 region	 around	 the	 carbonyl	 oxygen	 is	
indicative	 of	 the	 existence	 of	 higher	 negative	 electrostatic	
potential	 indicating	 favorable	 interaction	 energy	 with	
electronic	 density	 acceptors.	 It	 should	 be	 noted	 that,	 due	 to	
differences	 in	 electronegativity	 between	 carbon	 and	 fluorine	
atom,	 the	C2’	carbon	atoms	assume	a	“partial	positive	charge”	
that	contrasts	with	 the	partial	negative	charge	distribution	on	
compounds	 that	 do	 not	 have	 fluoridated	 substitution	 at	 that	
site.	
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Figure	6.	The	electrostatic	potential	(ESP),	mapped	on	an	electron	density	surface	(that	was	given	
by	SCF)	for	2.a	(7‐Cl‐1‐Me‐2'H‐BZ)	and	for	2.c,	7‐NO2‐2’F‐BZ	combined	with	the	receptor	locals	of	
interaction	of	 the	α1β2γ2	GABAA	subtype	as	proposed	by	Clayton	and	co‐workers	 [23].	The	model	
presents	 two	 areas	 with	 two	 electronic	 acceptor	 interactions	 (H1	 and	 H2)	 three	 lipophilic	
interaction	regions	(L1,	L2,	L3)	as	well	as	regions	of	negative	steric	repulsion(S1,	S2	and	S3).	
	
	
In	 recent	 years,	 a	 unified	 model	 of	 receptor/pharma	
cophore	 for	 agonists,	 antagonists,	 and	 inverse	 agonists	 of	BZs	
site	 on	 GABAA	 receptor	 has	 been	 developed.	 This	 can	 be	
achieved	 by	 the	 combination	 of	 several	 techniques	 such	 as	
synthesis	of	drugs	with	 radioisotopic	markers	 and	 techniques	
for	mapping	the	receptor.	Clayton	et	al.	[23]	in	2007	proposed	a	
base	 model	 for	 the	 binding	 receptor/	 pharmacophore	 at	 the	
α1β2γ2	 GABAA	 receptor	 subtype	 that	 is	 depicted	 in	 Figure	 6.	
According	 to	 the	 author	 the	 model	 consists	 of	 two	 domains	
with	 acceptor	 (H1	 and	 H2).	In	 addition	 to	 these	 areas	 of	
connection,	there	are	three	regions	of	lipophilic	interaction	(L1,	
L2	and	L3)	as	well	as	regions	of	negative	steric	 repulsion	(S1,	
S2	 and	 S3).	In	 the	 same	 figure	 the	 receptor/	 pharmacophore	
model	 is	 overlapped	with	 the	benzodiazepines	 studied	 in	 this	
work	 shown	 as	 ESP	 mapped	 density	 surfaces.	 As	 mentioned	
before,	 the	 main	 structural	 differences	 between	 the	 BZs	
presented	in	this	study	concerns	C7	(either	–NO2	or	–Cl)	and	C2’	
substituents	(which	may	be	–H,	–Cl	or	–F).	
The	 substituent	 at	 C7	 position	 interacts	 with	 a	 lipophilic	
region	 of	 the	 receptor	 by	 the	 proximity	 of	 residues	 of	 valine	
and	 glycine.	The	 –Cl	 substituent	 is	 reasonably	 lipophilic	 and	
more	 lipophilic	 than	 –NO2	 (judging	 by	 the	 π	 (aromatic)	
hydrophobic	 descriptor	which	 is	 0.71	 for	 –Cl	 and	 –0.28	 for	 –
NO2),	the	latter	being	more	hydrophilic	[24].	This	suggests	that	
benzodiazepines	 belonging	 to	 G1	 present	 a	 more	 favorable	
interaction	at	this	site	than	those	from	G2.	
The	 electron	 acceptor	 interaction	 in	 the	 H2	 region	 is	well	
illustrated	 by	 the	 quantitative	 study	made	 here.	 As	 shown	 in	
Figure	 6,	 the	 presence	 of	 the	 highly	 polarized	 C2’–F	 aromatic	
residue	 may	 provide	 another	 binding	 to	 H2	 local	 besides	 the	
unpaired	 electrons	 of	 imine	 N4.	 In	 fact,	 monosubstitution	 of	
fluorine	 in	 aromatic	 groups	 in	 drugs	 can	 lead	 to	 increased	
protein	 binding.	 Razgulin	 and	 Mecozzi,	 have	 highlighted,	
through	quantitative	computational	chemistry	calculations,	the	
role	of	carbon	bonding	to	the	aromatic	substituent	fluorine	and	
its	 influence	 on	 intermolecular	 interactions.	In	 their	 study,	 a	
series	of	representative	compounds	with	medical	interest	were	
used	 in	 which	 several	 aromatic	 C‐H	 bonds	 were	 replaced	 by	
their	 fluoro	 aromatic	 like	 compounds.	 These	 studies	
demonstrate	 that	 the	 binding	 of	 aromatic	 carbon	 to	 fluorine	
can	 participate	 in	 the	 formation	 of	 hydrogen	 bonds	 and	 can	
also	interact	strongly	with	positively	charged	molecules	[22].		
	
4.	Conclusion	
	
The	analysis	of	the	results	obtained	in	this	work	lead	to	the	
conclusion	that,	of	the	set	of	compounds	studied,	1.a	(and	their	
active	 metabolites	 1.c	 and	 1.d)	 are	 the	 BZs	 with	 the	 best	
electronic	 characteristics	 for	 interaction	 with	 the	 receptor	
presented	here.	 Since	 the	model	 refers	 to	 the	α1β2γ2	 sub‐type	
whose	 main	 effects	 are	 sedation,	 ataxia	 and	 anterograde	
amnesia	 [11,12]	drugs	belonging	 to	G1,	with	 exception	of	1.a,	
presents	 more	 pronounced	 effects	 on	 sedation	 [9]	 and	 side‐
effects	 as	 hypnotic,	 anxiolitic	 and	 myorelaxants.	In	 fact,	 with	
regard	 to	 their	 primary	 pharmacological	 action	 diazepam	1.a	
has	 a	 markedly	 anxiolytic	 action,	 being	 a	 full	 agonist	 of	 BZs	
receptors,	while	 flurazepam	1.b	has	a	hypnotic	action	[25,26].	
In	 the	 group	 of	 7–NO2–benzodiazepines	 the	 pharmacological	
effects	 are	 more	 dispersed:	 nitrazepam	 acts	 as	 the	 anti‐
convulsant,	clonazepam	as	antiepileptic	[27]	and	is	used	as	an	
aid	 on	 treatment	 of	 depressive	 disorders	 [28].	 Nevertheless	
compounds	with	C2’–F	substitution	such	as	flurazepam	[26]	1.b	
and	flunitrazepam	[29]	2.b	are	mainly	hypnotic‐sedatives.	The	
compounds	 with	 –NO2	 groups	 on	 C7	 and	 –Cl	 at	 C2’	 present	
anticonvulsant	 activities	 and	 may	 have	 more	 affinity	 for	
another	subtype	receptor,	such	as	the	α3β2γ2	receptor	[8,10,30].	
This	 study	 contributes,	 with	 relevant	 data,	 to	 the	 systematic	
three‐dimensional	 quantitative	 relations	 between	 molecular	
properties	and	their	biological	activity	(3D‐QSAR	relationships)	
and	 aids	 the	 understanding	 of	 structural	 mechanisms	 of	
benzodiazepine	modulation	at	the	GABA	receptors	[31].	
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